A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))

PHASE3CompletedINTERVENTIONAL
Enrollment

528

Participants

Timeline

Start Date

February 1, 2011

Primary Completion Date

October 1, 2011

Study Completion Date

October 19, 2011

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Fluticasone Furoate 100mcg/Vilanterol 25mcg

Inhalation Powder

DRUG

Fluticaosne Propionate 500mcg/Salmeterol 50mcg

Inhalation Powder

Trial Locations (66)

1070

GSK Investigational Site, Brussels

1100

GSK Investigational Site, Quezon City

1101

GSK Investigational Site, Quezon City

1200

GSK Investigational Site, Brussels

2650

GSK Investigational Site, Edegem

3600

GSK Investigational Site, Genk

4217

GSK Investigational Site, Lipa City

5000

GSK Investigational Site, Jaro, Iloilo City

5004

GSK Investigational Site, Bouge

6060

GSK Investigational Site, Gilly

9000

GSK Investigational Site, Ghent

10003

GSK Investigational Site, Cáceres

10117

GSK Investigational Site, Berlin

10787

GSK Investigational Site, Berlin

10789

GSK Investigational Site, Berlin

13915

GSK Investigational Site, Marseille

14057

GSK Investigational Site, Berlin

18009

GSK Investigational Site, Cherkassy

20014

GSK Investigational Site, San Sebastián

20099

GSK Investigational Site, Sesto S. Giovanni MI

20253

GSK Investigational Site, Hamburg

28040

GSK Investigational Site, Madrid

28223

GSK Investigational Site, Pozuelo de Alarcón/Madrid

29609

GSK Investigational Site, Brest

30159

GSK Investigational Site, Hanover

33604

GSK Investigational Site, Pessac

34295

GSK Investigational Site, Montpellier

35013

GSK Investigational Site, Cittadella PD

37134

GSK Investigational Site, Verona

39112

GSK Investigational Site, Magdeburg

46015

GSK Investigational Site, Valencia

48903

GSK Investigational Site, Barakaldo (Vizcaya)

56124

GSK Investigational Site, Pisa

59000

GSK Investigational Site, Lille

60389

GSK Investigational Site, Frankfurt am Main

60596

GSK Investigational Site, Frankfurt am Main

61035

GSK Investigational Site, Kharkiv

62408

GSK Investigational Site, Béthune

70021

GSK Investigational Site, Acquaviva Delle Fonti BA

76018

GSK Investigational Site, Ivano-Frankivsk

80809

GSK Investigational Site, Munich

82100

GSK Investigational Site, Benevento

84100

GSK Investigational Site, Salerno

115093

GSK Investigational Site, Moscow

115446

GSK Investigational Site, Moscow

125367

GSK Investigational Site, Moscow

150003

GSK Investigational Site, Yaroslavl

420015

GSK Investigational Site, Kazan'

454034

GSK Investigational Site, Chelyabinsk

650000

GSK Investigational Site, Kemerovo

06002

GSK Investigational Site, Nice

04509

GSK Investigational Site, Delitzsch

01307

GSK Investigational Site, Dresden

04207

GSK Investigational Site, Leipzig

00135

GSK Investigational Site, Rome

06156

GSK Investigational Site, Perugia

Unknown

GSK Investigational Site, Bialystok

42-200

GSK Investigational Site, Częstochowa

92-107

GSK Investigational Site, Lodz

93-329

GSK Investigational Site, Lodz

63-400

GSK Investigational Site, Ostrów Wielkopolski

41-940

GSK Investigational Site, Piekary Śląskie

43-365

GSK Investigational Site, Wilkowice

03114

GSK Investigational Site, Alicante

03680

GSK Investigational Site, Kiev

04107

GSK Investigational Site, Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01342913 - A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP)) | Biotech Hunter | Biotech Hunter